HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

soraphen A

from myxobacteria Sorangium cellulosum; structure given in first source

Also Known As:

soraphen A(1alpha)

Networked: 10 relevant articles (1 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Lactones: 1549
  - Macrolides: 4391
    - soraphen A: 10
  - Polyketides: 231
    - Macrolides: 4391
      - soraphen A: 10
Polycyclic Compounds: 6
- Macrocyclic Compounds: 15
  - Polyketides: 231
    - Macrolides: 4391
      - soraphen A: 10

Experts

1.	Müller, Rolf: 6 articles (10/2021 - 11/2014)
2.	Swinnen, Johannes V: 3 articles (01/2014 - 09/2007)
3.	Brönstrup, Mark: 2 articles (10/2021 - 01/2021)
4.	Harmrolfs, Kirsten: 2 articles (10/2021 - 11/2014)
5.	Rox, Katharina: 2 articles (10/2021 - 01/2021)
6.	Berod, Luciana: 2 articles (01/2021 - 11/2014)
7.	Lochner, Matthias: 2 articles (01/2021 - 11/2014)
8.	Sparwasser, Tim: 2 articles (01/2021 - 11/2014)
9.	Daniëls, Veerle W: 2 articles (01/2014 - 10/2010)
10.	Smans, Karine: 2 articles (01/2014 - 10/2010)

Related Diseases

1.	Neoplasms (Cancer) 09/01/2007 - "Here, using the potent ACC inhibitor soraphen A, a macrocyclic polyketide from myxobacteria, we show that ACC activity in cancer cells is essential for proliferation and survival. " 01/01/2014 - "Consequently, cancer cells grown in lipid-reduced conditions became more dependent on de novo lipid synthesis pathways and were more sensitive to inhibitors of lipogenic pathways, like Soraphen A and Simvastatin. " 10/15/2010 - "Reversal of the lipogenic switch in cancer cells by treatment with the lipogenesis inhibitor soraphen A or by targeting lipogenic enzymes with small interfering RNA leads to a marked decrease in saturated and mono-unsaturated phospholipid species and increases the relative degree of polyunsaturation. " 01/01/2018 - "Various acetyl-CoA carboxylase 1 (ACC1), and fatty acid synthase (FASN) inhibitors (like Soraphen A and Cerulenin) as well as genetic knockdown approaches were employed to study the effects of disturbed phospholipid composition on membrane properties and its functional impact on cancer progression. "
2.	Infections 01/01/2021 - "Importantly, pharmacological inhibition of ACC1 by the natural compound soraphen A mirrored the anti-inflammatory effects of T-cell-specific targeting, but also enhanced susceptibility toward infection with C. " 10/08/2021 - "Physiologically Based Pharmacokinetic/Pharmacodynamic Model for the Treatment of Dengue Infections Applied to the Broad Spectrum Antiviral Soraphen A."
3.	Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome) 01/01/2019 - "Pretreatment with calorie restriction (CR; with 30% reduction of food for 4 weeks before middle cerebral artery occlusion) or post-treatment with ACC1 inhibitor, soraphen A were both used to test the effect of ACC1 modulation on poststroke neuroinflammation. "
4.	Virus Diseases (Viral Diseases) 03/13/2015 - "Soraphen A: A Probe for Investigating the Role of de Novo Lipogenesis during Viral Infection."
5.	Viremia 10/08/2021 - "We report the construction of the first physiologically based pharmacokinetic/pharmacodynamic (PBPK/PD) model that predicts viremia levels in relevant target organs based on preclinical data with the broad spectrum antiviral soraphen A (SorA), an inhibitor of the host cell target acetyl-CoA-carboxylase. "

Related Drugs and Biologics

1.	Phospholipids (Phosphatides)
2.	Small Interfering RNA (siRNA)
3.	Enzymes
4.	Acetyl-CoA Carboxylase
5.	Fatty Acid Synthases (Fatty Acid Synthase)
6.	Cerulenin
7.	Polyketides
8.	Simvastatin (Zocor)
9.	Cytokines
10.	Lipids

Related Therapies and Procedures

1.	Therapeutics